(NYSE: JNJ) Johnson & Johnson's forecast annual revenue growth rate of 4.31% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.21%.
Johnson & Johnson's revenue in 2025 is $92,149,000,000.On average, 26 Wall Street analysts forecast JNJ's revenue for 2025 to be $228,179,520,520,216, with the lowest JNJ revenue forecast at $220,852,854,115,034, and the highest JNJ revenue forecast at $237,920,300,617,602. On average, 26 Wall Street analysts forecast JNJ's revenue for 2026 to be $240,295,865,588,174, with the lowest JNJ revenue forecast at $231,909,109,338,112, and the highest JNJ revenue forecast at $252,055,634,981,036.
In 2027, JNJ is forecast to generate $251,911,077,274,916 in revenue, with the lowest revenue forecast at $238,421,433,998,818 and the highest revenue forecast at $266,015,090,802,024.